{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:57:26Z","timestamp":1790935046373,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.ahjo.2024.100386","type":"journal-article","created":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T21:51:54Z","timestamp":1711317114000},"page":"100386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review"],"prefix":"10.1016","volume":"41","author":[{"given":"Arun J.","family":"Sanyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoor","family":"Husain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystel","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal Kant","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsan","family":"Shoeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot B.","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0005","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ahjo.2024.100386_bb0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.ahjo.2024.100386_bb0015","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 Global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.ahjo.2024.100386_bb0020","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.ahjo.2024.100386_bb0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","article-title":"The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient-reported outcomes study","volume":"1","author":"Balp","year":"2019","journal-title":"JHEP Rep."},{"issue":"3","key":"10.1016\/j.ahjo.2024.100386_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11901-020-00530-0","article-title":"Cardiovascular disease in nonalcoholic steatohepatitis: screening and management","volume":"19","author":"Shroff","year":"2020","journal-title":"Curr. Hepatol. Rep."},{"issue":"9","key":"10.1016\/j.ahjo.2024.100386_bb0035","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.ahjo.2024.100386_bb0040","series-title":"Effective Public Healthcare Panacea Project. Quality Assessment Tool for Quantitative Studies","year":"2010"},{"key":"10.1016\/j.ahjo.2024.100386_bb0045","doi-asserted-by":"crossref","first-page":"S833","DOI":"10.1016\/S0168-8278(18)31942-1","article-title":"Clinical outcomes in biopsy-proven NAFLD patients from the HEPAmet Spanish Registry","author":"Ampuero","year":"2018","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0050","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/liv.14080","article-title":"Evidence of bias during liver transplant evaluation of non-alcoholic steatohepatitis cirrhosis patients","volume":"39","author":"Danford","year":"2019","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.ahjo.2024.100386_bb0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/MCG.0b013e31822fb3f7","article-title":"Cardiovascular disease and nonalcoholic fatty liver disease: does histologic severity matter?","volume":"46","author":"Domanski","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"issue":"8","key":"10.1016\/j.ahjo.2024.100386_bb0060","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jclinane.2013.06.001","article-title":"Coronary artery disease and its risk factors in patients presenting for liver transplantation","volume":"25","author":"Gologorsky","year":"2013","journal-title":"J. Clin. Anesth."},{"issue":"S1","key":"10.1016\/j.ahjo.2024.100386_bb0065","article-title":"1725 Invasive cardiac risk stratification of NASH patients prior to liver transplant","volume":"72","author":"Herndon","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.ahjo.2024.100386_bb0070","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/lt.25863","article-title":"Outcomes of liver transplantation among older recipients with nonalcoholic steatohepatitis in a large multicenter US cohort: the re-evaluating age limits in transplantation consortium","volume":"26","author":"Kwong","year":"2020","journal-title":"Liver Transpl."},{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0075","doi-asserted-by":"crossref","first-page":"E606","DOI":"10.1111\/j.1399-0012.2011.01497.x","article-title":"Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more","volume":"25","author":"Park","year":"2011","journal-title":"Clin. Transpl."},{"issue":"5","key":"10.1016\/j.ahjo.2024.100386_bb0080","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s12072-021-10209-3","article-title":"Innovative target exploration of NC. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease","volume":"15","author":"Park","year":"2021","journal-title":"Hepatol. Int."},{"issue":"1, Supplement","key":"10.1016\/j.ahjo.2024.100386_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/S0618-8278(19)31128-4","article-title":"FRI-389: impact of coronary artery disease on long term mortality after liver transplantation","volume":"70","author":"Patel","year":"2019","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.ahjo.2024.100386_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/lt.25012","article-title":"Coronary artery disease in decompensated patients undergoing liver transplantation evaluation","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transpl."},{"issue":"1","key":"10.1016\/j.ahjo.2024.100386_bb0095","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.dld.2017.08.022","article-title":"Liver transplantation for NASH cirrhosis is not performed at the expense of major post-operative morbidity","volume":"50","author":"van den Berg","year":"2018","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.ahjo.2024.100386_bb0100","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.25855","article-title":"Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events","volume":"56","author":"VanWagner","year":"2012","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ahjo.2024.100386_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34988-2","article-title":"Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease","volume":"8","author":"Viglino","year":"2018","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.ahjo.2024.100386_bb0110","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s11695-011-0521-z","article-title":"Nonalcoholic steatohepatitis (NASH) does not increase complications after laparoscopic bariatric surgery","volume":"21","author":"Weingarten","year":"2011","journal-title":"Obes. Surg."},{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0115","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/ctr.12364","article-title":"Improved survival outcomes in patients with non-alcoholic steatohepatitis and alcoholic liver disease following liver transplantation: an analysis of 2002-2012 United Network for Organ Sharing data","volume":"28","author":"Wong","year":"2014","journal-title":"Clin. Transpl."},{"issue":"9","key":"10.1016\/j.ahjo.2024.100386_bb0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1477-2574.2012.00497.x","article-title":"Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases","volume":"14","author":"Kennedy","year":"2012","journal-title":"HPB (Oxford)"},{"issue":"13","key":"10.1016\/j.ahjo.2024.100386_bb0125","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.cgh.2019.04.033","article-title":"Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies","volume":"17","author":"Nagai","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.ahjo.2024.100386_bb0130","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/tri.13001","article-title":"Cardiovascular mortality among liver transplant recipients with nonalcoholic steatohepatitis in the United States-a retrospective study","volume":"30","author":"Satapathy","year":"2017","journal-title":"Transpl. Int."},{"issue":"10","key":"10.1016\/j.ahjo.2024.100386_bb0135","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s10620-013-2743-5","article-title":"Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"58","author":"Stepanova","year":"2013","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.ahjo.2024.100386_bb0140","first-page":"79","article-title":"Frequency of cardiovascular events and effect on survival in liver transplant recipients for cirrhosis due to alcoholic or nonalcoholic steatohepatitis","volume":"14","author":"Piazza","year":"2016","journal-title":"Exp. Clin. Transplant."},{"issue":"12","key":"10.1016\/j.ahjo.2024.100386_bb0145","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/liv.12872","article-title":"Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis","volume":"35","author":"VanWagner","year":"2015","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0150","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurjpc\/zwab212","article-title":"Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Alon","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ahjo.2024.100386_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.ahjo.2024.100386_bb0160","first-page":"4","article-title":"Risk of cardio-nephro-metabolic disease from NAFLD to MAFLD: fact or fiction?","volume":"1","author":"Hassouneh","year":"2021","journal-title":"Metab. Target Organ Damage"},{"issue":"5","key":"10.1016\/j.ahjo.2024.100386_bb0165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11892-021-01383-7","article-title":"The relationship between type 2 diabetes, NAFLD, and cardiovascular risk","volume":"21","author":"Caussy","year":"2021","journal-title":"Curr. Diab. Rep."},{"issue":"7","key":"10.1016\/j.ahjo.2024.100386_bb0170","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","volume":"79","author":"Muzurovic","year":"2022","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ahjo.2024.100386_bb0175","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/1570161115666170621082910","article-title":"Statins: an under-appreciated asset for the prevention and the treatment of NAFLD or NASH and the related cardiovascular risk","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ahjo.2024.100386_bb0180","doi-asserted-by":"crossref","DOI":"10.1177\/1179552218787502","article-title":"An evidence-based review of statin use in patients with nonalcoholic fatty liver disease","volume":"11","author":"Sigler","year":"2018","journal-title":"Clin. Med. Insights Gastroenterol."},{"key":"10.1016\/j.ahjo.2024.100386_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106367","article-title":"SACRED: effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: statins and cirrhosis: reducing events of decompensation","volume":"104","author":"Kaplan","year":"2021","journal-title":"Contemp. Clin. Trials"},{"issue":"1","key":"10.1016\/j.ahjo.2024.100386_bb0190","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr. Rev."},{"issue":"6","key":"10.1016\/j.ahjo.2024.100386_bb0195","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["American Heart Journal Plus: Cardiology Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602224000296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666602224000296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T04:07:41Z","timestamp":1714363661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666602224000296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":39,"alternative-id":["S2666602224000296"],"URL":"https:\/\/doi.org\/10.1016\/j.ahjo.2024.100386","relation":{},"ISSN":["2666-6022"],"issn-type":[{"value":"2666-6022","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal Plus: Cardiology Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahjo.2024.100386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100386"}}